ABSTRACT-Rationale: Microvesicles (MV) act as a nonsoluble means of intercellular communication, with effector roles in disease pathogenesis and potentially as biomarkers. Previously, we reported that neutrophil MV expressing alpha-2-macroglobulin (A2MG) are protective in experimental sepsis and associate with survival in a small cohort of patients with sepsis due to community acquired pneumonia (CAP). Objectives: To characterize MV profiles in sepsis due to CAP or fecal peritonitis (FP) and determine their relation to outcome. To investigate the effects of novel sepsis treatments (granulocytemacrophage colony stimulating factor (GM-CSF) and interferon-U (IFN-g)) on MV production and functions in vitro. Methods: Flow cytometry analysis of MV identified the cell of origin and the proportion of A2MG expression in the plasma of patients with sepsis secondary to CAP (n ¼ 60) or FP (n ¼ 40) and compared with healthy volunteers (HV, n ¼ 10). The association between MV subsets and outcome was examined. The ability of GM-CSF and IFN-g on A2MG þve MV production from whole blood was examined together with the assessment of their effect on neutrophil and endothelial functions. Results: Circulating cell-derived and A2MG
INTRODUCTION
The incidence of sepsis continues to increase and the associated morbidity and mortality remain persistently high (1, 2) . Lack of progress in combating sepsis reflects our limited understanding of the complex biological pathways that regulate immune responses (3) . It is now recognized that the immune dysfunction evident in many patients with sepsis is associated with a predominant anti-inflammatory response that drives further morbidity and mortality (4) . Novel strategies to reverse this immune-paresis, such as granulocyte macrophage colonystimulating factor (GM-CSF) and interferon gamma (IFN-g) (5-7), are therefore being investigated.
An appropriately regulated host response relies on effective cell-to-cell communication. A novel means of nonsoluble communication has recently emerged centered on plasma membrane-shed particles, called microvesicles (MV). MV are heterogeneous, submicron packages surrounded by an outer membrane with surface proteins derived from the parental cell (8) . In sepsis, MV may display both pro-and anti-inflammatory properties (9, 10) . This heterogeneity resulted in conflicting reports regarding the relation between circulating levels of MV and outcome (10, 11) . Our group reported that neutrophils produce distinct MV phenotypes in response to specific activation stimuli (12) . We found that neutrophil MV expressing the protein alpha-2-macroglobulin (A2MG) promote a pro-inflammatory phenotype when incubated with innate immune cells, as well as improving pathogen clearance and overall survival in a murine model of peritonitis (13) . Increased levels of A2MG þve MV were associated with survival in patients with sepsis and organ dysfunction due to community acquired pneumonia (CAP) (13) .
In this study, we extend these findings to a larger cohort of patients with sepsis due to CAP or faecal peritonitis (FP), performing more detailed analyses of MV profiles including temporal quantification. We also investigated whether the A2MG þve ''beneficial'' subset of MV could be produced in whole blood treated with granulocyte-macrophage colonystimulating factor (GM-CSF) or interferon g (IFN-g) and further examined their functional effects in vitro.
N Â ðD=VÞ ¼ MV=mL
Where N is the total number of events acquired, V is the sample volume (30 mL), and D is the dilution (1 in 40) . 
Human umbilical cord endothelial cells (HUVEC) MV uptake
MV labeled with BODIPY were incubated with HUVEC for 4 h. In some experiments, HUVEC were pre-incubated with cytochalasin B (10 mM). Imagestream X-II with confirmation by confocal microscopy (Zeiss Laser LSM 710) was used to detect the presence of MV inside the HUVEC.
HUVEC functional assays
Adhesion molecule and tissue factor expression were quantified by flow cytometry, following incubation with MV in the absence or presence of lipopolysaccharide (LPS). Reactive oxygen species (ROS) and nitric oxide (NO) production were quantified using 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (H 2 DCFDA) and Griess reagent, respectively. Supernatants were tested for IL-8 concentration using enzyme-linked immunosorbent assay. The permeability of confluent HUVEC on 0.2 mm tissue culture inserts was measured by the recovery of fluorescein isothiocyanate-labeled Dextran.
Neutrophil functional assays
CD11b expression was quantified using flow-cytometry (Supplemental Digital Content 04, http://links.lww.com/SHK/A642). ROS production was þve cell-derived MVs from the same cohorts. Data expressed as median and Kruskal-Wallis and Dunn tests were used for comparison. * : P < 0.05, ** : P < 0.01. *** : P < 0.001. assessed using H 2 DCFDA and phagocytosis was tested following incubation with BODIPY-labelled Escherichia coli. The chemotaxis assay was conducted as previously described (15) : neutrophils were incubated with MV in the presence or absence of LPS (100 ng/mL). Formyl-Methionyl-LeucylPhenylalanine (1 mM) was used as the chemoattractant. In some assays a neutralizing monoclonal antibody against Alpha-2-macroglobulin (A2MG) was added.
Neutrophil-endothelial interaction under flow
Confluent HUVEC were stimulated with LPS in the presence of absence of MV for 4 h. Neutrophils were perfused at 1 dyne/cm 2 for 8 min. Six random fields were recorded for 10 s for off-line analysis of cell capture.
RESULTS

Patients
One hundred patients recruited to the Genomic Advances in Sepsis study with sepsis due to CAP (n ¼ 60) or FP (n ¼ 40) were included in this study. Patients were selected to include equal number of survivors and nonsurvivors (at 28 days postadmission to ICU). The baseline demographic characteristics, comorbidities, severity scores, and cell counts on admission to ICU were comparable between the two cohorts (Supplemental Digital Content 05, http://links.lww.com/SHK/A642). HV were significantly younger than both patient groups and their neutrophil count was significantly lower, while their monocyte and lymphocyte counts were higher. CAP and FP non-survivors were older and had higher severity scores on admission (Supplemental Digital Content 06 and Supplemental Digital Content 07, http://links.lww.com/SHK/A642, respectively) compared with survivors. There were no significant differences in differential leucocyte counts between survivors and nonsurvivors in either cohort (Supplemental Digital Content 06 and Supplemental Digital Content 07, http://links.lww.com/SHK/ A642).
Characterization of plasma MV
MV phenotype was investigated by flow cytometry in a gate formulated using fluorescent beads of known diameter (0.1 and 1 mm) and focusing on vesicles expressing phosphatidylserine, hence able to bind Annexin V: Figure 1A to C provide representative images for this strategy. At day one postadmission to ICU, the numbers of neutrophil-, monocyte-, and lymphocyte-derived MV were significantly higher in CAP compared with FP patients and HV (Fig. 1, D-F) . MV numbers in FP were not significantly different to HV (Fig. 1) ; platelet-and erythrocyte-derived MV did not differ significantly between the three cohorts. MV derived from endothelial cells were significantly elevated in CAP patients compared with HV, but not FP compared with HV ( Fig. 1I) . We then characterized MV according to their surface expression of A2MG. Figure 2A and B illustrates how the identification was conducted, using CD41 staining for platelet derived MV as an example. At day 1, the number of total A2MG
þve MV derived from all cellular sources was significantly higher in CAP compared with FP patients and HV (Fig. 2C ). Further analyses demonstrated that A2MG
þve MV derived from each cell types were all significantly higher in CAP compared with FP and HV (Fig. 2, D-H ).
MV profiles in CAP survivors and non-survivors
We proceeded to investigate the relationship between MV subsets and survival in sepsis. In patients with CAP, endothelial MV numbers were significantly higher in non-survivors. There were no significant differences in the other MV subsets between CAP survivors and non-survivors (Supplemental Digital Content 08, http://links.lww.com/SHK/A642). When MV were further stratified according to A2MG expression, the total number of A2MG þve MV from all the sources was 2-fold higher in CAP survivors compared with non-survivors (Fig. 3A) . In particular, neutrophil-and monocyte-derived A2MG þve MV were 2-and 7-fold higher in CAP survivors than in non-survivors, respectively (Fig. 3 , B and C), with no significant differences for the other subsets (Fig. 3, D-F) . FP nonsurvivors displayed 3-and 2-fold higher levels of neutrophil-and erythrocyte-derived MV in comparison with survivors, respectively (Supplemental Digital Content 09, http://links.lww.com/ SHK/A642). Erythrocyte derived A2MG
þve MV were also significantly higher in non-survivors of FP (Supplemental Digital Content 10, http://links.lww.com/SHK/A642).
Subsequently, we characterized MV profiles in the plasma of CAP patients at days 3 and 5 postadmission to ICU to establish whether the day 1 MV profile is sustained as the disease progresses. This analysis indicated that the differences between survivors and non-survivors persisted; survivors of CAP exhibited higher levels of A2MG þve MV derived from neutrophils and monocytes, as well as higher total A2MG þve counts. No differences were evident when comparing lymphocyte, endothelial, and platelet A2MG
þve MV phenotypes (Supplemental Digital Content 11 and Supplemental Digital Content 12, http:// links.lww.com/SHK/A642).
Modulation of A2MG
Rve MV production by GM-CSF and IFN-g Next, we questioned whether the specific subsets of MV which discriminated between survivors and non-survivors in CAP could be modulated by novel potential therapies for sepsis. The effect of GM-CSF and IFN-g on whole blood production of A2MG þve MV was investigated. Preliminary analyses were undertaken to elucidate the optimum incubation times and concentration with respect to A2MG
þve MV production (Fig. 4A) . The optimal conditions were 30 min following stimulation with 100 ng/mL for GM-CSF and 3 h following stimulation with 50 ng/mL IFN-g.
Effect of MV derived from GMCSF or IFN-g stimulated whole blood on endothelial cells and neutrophil responses
To test whether HUVEC internalized MV, MV from cytokinestimulated whole blood were labeled with the fluorescent dye BODIPYand incubated with the cells, with or without cytochalasin B. More than 85% of HUVEC endocytosed the fluorescent MV, but this rate of internalization was reduced to 15% in the HUVEC pretreated with cytochalasin B. Uptake of MV was confirmed using confocal microscopy demonstrating that HUVEC contain fluorescent MV following 2 h incubation ( Fig. 4 ; Supplemental Digital Content 13, http://links.lww.com/SHK/A642).
Next, we tested the effect of MVs derived from GMCSF or IFN-g-stimulated whole blood on HUVEC responses in the presence or absence of LPS. The MV did not alter either ICAM-1 or VCAM-1 expression following 4 h of incubation with LPS (Supplemental Digital Content 14, http://links.lww.com/SHK/ A642). Similarly, expression of CD62E or CD31 was not altered by exposure to cytokine-elicited MV (data not shown).
In contrast, incubation of HUVEC with GM-CSF-stimulated MV, but not IFN-g-stimulated MV, significantly enhanced ROS production in both the presence and the absence of LPS (Supplemental Digital Content 15, http://links.lww.com/ SHK/A642). Both MV populations reduced the increase in HUVEC monolayer permeability induced by LPS (Fig. 5) .
Production of endothelial-derived mediators was then measured. NO release was significantly enhanced by both GM-CSF and IFN-g MV when added to HUVEC in the presence of LPS (Supplemental Digital Content 16, http://links.lww.com/SHK/ A642). Similarly, both MV populations augmented the release of IL-8, irrespective of LPS addition (Supplemental Digital Content 17, http://links.lww.com/SHK/A642).
Next, we tested the effects of MV on neutrophil functions. GM-CSF-and IFN-g-derived MV upregulated cell-surface expression of CD11b (Supplemental Digital Content 18, http://links.lww.com/SHK/A642). This effect was accompanied by enhanced phagocytosis (Fig. 5A) . Neutrophil ROS production and chemotaxis were not modified by either MV subset, irrespective of the presence or absence of LPS (Supplemental Digital Content 19 and Supplemental Digital Content 20, http://links.lww.com/SHK/A642). To test whether A2MG expressed on MV was contributing to some these effects, an anti-A2MG blocking antibody was used. The antibody, tested at 0.1 to 5 mg/mL, abrogated the enhancing effect of GM-CSF-derived MV on neutrophil phagocytosis at the maximal concentration tested (Fig. 5B) . Such an enhancing effect on phagocytosis was not mimicked by soluble factors as it is absent in GM-CSF-treated plasma following removal of MV (Fig. 5B) .
Finally, we investigated whether GM-CSF and IFN-g stimulated MV could affect neutrophil-endothelial interaction under flow conditions, since this phenomenon is known to be modulated by soluble and MV-associated A2MG (13) . The addition of LPS alone to HUVEC promoted interaction with flowing neutrophils; addition of GMCSF and IFN-g stimulated MV, but not MV from paired unstimulated blood, enhanced neutrophil capture, rolling, adhesion, and transmigration (Fig. 5) .
DISCUSSION
In this study of patients with infection and organ dysfunction, CAP and FP plasma samples displayed different MV profiles. Higher levels of A2MG
þve MV were quantified in survivors of sepsis secondary to CAP, an association that was not apparent in those with FP. These findings highlight the increasingly recognized heterogeneity of the septic response, in this case related to the infectious aetiology, despite the similarity of the two cohorts in terms of demographics, comorbidities, severity scores, and cell counts. The observed differences between survivors and nonsurvivors of CAP may reflect the capacity of the A2MG þve MV subset to promote potentially beneficial immune responses (13) . These results may indicate that approaches aiming at stimulating the immune system may represent a valid therapeutic option. Of note, therefore, was the ability of two recently trialled therapies, GM-CSF and IFN-g, to augment production of this subset of MV, with at least partial validation of A2MG functional role on some of the effects promoted by cytokine-stimulated MV on enhanced pathogen clearance functions of endothelial cells and neutrophils in vitro.
Previous attempts to profile MV in sepsis have yielded conflicting results (11, (16) (17) (18) : platelet-derived MV are elevated in sepsis compared with HV (10, 18) albeit this outcome is not observed consistently (11), while endothelial-derived MV are either elevated (18) , similar (19) or even lower (16) compared with HV samples. Numbers of monocyte-derived MV could be either no different to HV (10, 18) or could not be detected (20) . In relation to the outcome of sepsis, it has been reported in heterogeneous cohorts that endothelial-derived MV are elevated in survivors, whereas there were no significant differences between survivors and non-survivors for plateletderived MV (11) . We believe these inconsistent findings may be due to the inclusion of patients with a variety of infectious aetiologies and differences in methodology. In the present study MV numbers in FP patients were only modestly increased when compared with HV, whereas more significant changes were observed in CAP patients, particularly in the granulocyte and monocyte MV subsets despite similar illness severity as determined by APACHE II score. We also identified a specific MV (A2MG þve ) subset that was associated with survival selectively in CAP sepsis. Importantly, these differences in MV subsets could not be ascribed to changes in circulating parent cells, hence it is plausible that the activation status of the cells, rather than their absolute number, determines the concentration of specific MV in the circulation.
It is possible that the differences between the MV profiles observed in CAP and FP patients might be due to differences in the time course of each disease. CAP patients have often been unwell for many days prior to ICU admission, whereas FP patients usually have a rapid and fairly recent onset of illness. Also, CAP is caused by specific bacterial or atypical pathogens and is commonly preceded, or caused by viral infection (21) . The majority of causative organisms in CAP are gram-positive (22) while FP is due to peritoneal contamination with a mixture of gram-negative, gram-positive, and anaerobic organisms (23) . In FP, the concentration of cytokines is much higher in the peritoneal cavity compared with plasma, suggesting that there is a considerable degree of compartmentalisation that may have little impact on the production of plasma MV (24) . The host /mL) was incubated with freshly prepared neutrophils for 60 min, prior to addition of fluorescent heat killed E coli to assess the extent of phagocytosis by fluorescence plate reader. In some cases LPS (100 ng/mL) was added to the cells together with the MV. B, MV (1À2 Â 10 6 /mL), MV with A2MG antibody (0.1À5 mg/mL), cytokine supernatant free of MV (20 ml/mL) were incubated in the presence of LPS-or LPS alone-with freshly prepared neutrophils (1 Â 10 6 mL) for 60 min, prior to addition of fluorescent heat killed E coli. C, MV were incubated with human umbilical vein endothelial cells (HUVEC) and the extent of permeability determined using fluorescent dextran (70,000 kDa) and fluorescent plate reader. D and G, Effect of MV on neutrophil-endothelium interaction under flow. HUVEC were incubated with LPS (100 ng/mL) for 4 h, prior to addition of MV (1À2 Â 10 6 /mL) and flow of freshly prepared neutrophils. In all cases, data are mean AE SEM of 4 distinct preparations, these being MV, HUVEC or neutrophils, as required. LPS indicates lipopolysaccharide. One-way ANOVA and Bonferroni post-hoc tests were applied. response may also be modulated by surgical trauma in FP patients and the choice of antibiotics (25, 26) .
The extended analyses presented here indicate that in CAP, A2MG
þve MVare significantly elevated not only for the fraction of MV derived from neutrophils but also in those derived from erythrocytes, platelets, lymphocytes, and monocytes. This acute phase protein inhibits proteases and sequesters cytokines such as TNF-a and IL-6, facilitating their endocytosis (27) . Cytokine binding may underlie the ability of A2MG to enhance survival of endotoxaemic mice (28) . However, in a recent study conducted in experimental animals, we demonstrated that MV-incorporated A2MG activates specific innate immune responses, such as neutrophil activation and recruitment, responsiveness to IL-8 and phagocytosis (13) . Although A2MG production in the liver would be expected to increase in sepsis, it is unclear how this acute phase protein becomes incorporated into MV. We reasoned that-similar to albumin-A2MG may be part of the secretory vesicles and as such be present on the cell plasma membrane when MV bud from it (13) . In any case, coupled with our previous study (13) where a limited number of patient samples were analyzed, these new data highlight the importance of characterizing MV for at least two markers to identify potential associations with disease phenotypes.
The increased expression of A2MG þve MV in survivors of CAP sepsis persists into days 3 and 5 postadmission. However, we cannot ascertain whether this observation reflects the sustained production of A2MG from the liver or whether it is linked to the encapsulation of this protein in the MV, thereby promoting the optimal delivery and bio-actions, or both.
An important function of MV is to transfer their constituents into target cells. In murine models, neutrophil-derived proinflammatory MV can deliver A2MG into macrophages or deposit this acute phase protein onto endothelial monolayers (13) . The mechanism for MV internalization is via phagocytosis or macropinocytosis (29) . We present evidence here that endothelial cells internalized MV, a cellular uptake largely prevented by cytochalasin B which inhibits actin filament polymerization (30) .
Altogether these results identify A2MG þve MV as a useful marker associated with better outcome in CAP sepsis. To establish if this could also have a prognostic value for patient responsiveness to novel treatments for sepsis, we tested the effect of GM-CSF and IFN-g on MV production and function in vitro. We found that both cytokines augmented A2MG
þve MV production when incubated with whole blood. In functional terms, MV produced from whole blood stimulated by GM-CSF or IFN-g, enhanced IL-8 release, an effect more marked in the presence of LPS. In clinical trials, GM-CSF and IFN-g restored TNF-a levels, thereby sustaining the immune response to endotoxin in patients with sepsis, and reducing the incidence of hospital-acquired infection (5, (31) (32) (33) . In sepsis, IL-8 production from whole blood stimulated with endotoxin is inhibited (34) , a response that could be restored by GM-CSF (31) consistent with our data. Moreover, NO production was augmented by stimulated MV; intriguingly, this effect was associated with a reduction in endothelial permeability. MV from stimulated whole blood did not, however affect neutrophil chemotaxis or ROS production. Both GM-CSF and IFN-gderived MV increased the interaction between neutrophils and endothelial monolayers under flow, extending data produced with neutrophil-derived A2MG þ MV which also enhance bacterial clearance and resolution of inflammation in a murine model of sepsis (12, 13) . In assays of phagocytosis, GM-CSF and IFN-g-derived A2MG
þ MV promoted bacteria engulfment; in these settings we provided proof of concept for the functional involvement of A2MG through the use of an anti-A2MG antibody.
In summary, in this study we report the novel observation that in sepsis MV profiles vary significantly according to the source of infection. Increased plasma levels of A2MG þ MV are associated with survival in CAP sepsis but not in patients with FP. Stimulation of whole blood with GM-CSF and IFN-g enhances the production of A2MG þ MV which then induce pro-pathogen clearing effects in neutrophils and endothelial cells. These results underline the heterogeneity of MV profiles in sepsis, as well as their important role in pathogenesis and possibly as effectors linked to therapeutic interventions.
